$21.30
-0.44-2.02%
At Close: -
$21.30
00.00%
After Hours: Jul 3, 1:00 PM EDT
15 minutes delayed
Denali Therapeutics
DNLINASDAQ
Denali Therapeutics (NASDAQ:DNLI) Stock, Analyst Ratings, Price Targets, Predictions
Denali Therapeutics Inc has a consensus price target of $42, established from looking at the 42 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Wedbush, and Stifel on May 8, 2024. With an average price target of $49 between HC Wainwright & Co., Wedbush, and Stifel, there's an implied 130.05% upside for Denali Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Stifel
UBS
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Denali Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2024 | Buy Now | 346.01% | HC Wainwright & Co. | Andrew Fein | → $95 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 40.85% | Wedbush | Laura Chico | $31 → $30 | Maintains | Outperform | Get Alert |
| 05/08/2024 | Buy Now | 3.29% | Stifel | Paul Mattels | $26 → $22 | Maintains | Hold | Get Alert |
| 04/09/2024 | Buy Now | 50.23% | UBS | Esther Rajavelu | $70 → $32 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | 134.74% | Goldman Sachs | Salveen Richter | $73 → $50 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 346.01% | HC Wainwright & Co. | Andrew Fein | $105 → $95 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 45.54% | Wedbush | Laura Chico | → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 392.96% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2023 | Buy Now | 50.23% | Citigroup | David Hoang | → $32 | Initiates | → Buy | Get Alert |
| 11/20/2023 | Buy Now | 31.46% | JP Morgan | Jessica Fye | → $28 | Reinstates | → Overweight | Get Alert |
| 11/08/2023 | Buy Now | 45.54% | Wedbush | Laura Chico | → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 10/24/2023 | Buy Now | 64.32% | Cantor Fitzgerald | Charles Duncan | $85 → $35 | Assumes | → Overweight | Get Alert |
| 09/06/2023 | Buy Now | 78.4% | B. Riley Securities | Mayank Mamtani | → $38 | Initiates | → Buy | Get Alert |
| 08/31/2023 | Buy Now | 392.96% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | Buy → Buy | Get Alert |
| 08/31/2023 | Buy Now | 299.06% | Cantor Fitzgerald | Charles Duncan | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 08/22/2023 | Buy Now | 299.06% | Cantor Fitzgerald | Charles Duncan | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 08/10/2023 | Buy Now | 299.06% | Cantor Fitzgerald | Charles Duncan | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 45.54% | Wedbush | Laura Chico | $37 → $31 | Maintains | Outperform | Get Alert |
| 08/09/2023 | Buy Now | 392.96% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | Buy → Buy | Get Alert |
| 06/22/2023 | Buy Now | 299.06% | Cantor Fitzgerald | Charles Duncan | → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 06/21/2023 | Buy Now | 392.96% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 219.25% | Oppenheimer | Jay Olson | $70 → $68 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 73.71% | Wedbush | Laura Chico | $38 → $37 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 392.96% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | → Buy | Get Alert |
| 04/12/2023 | Buy Now | 195.77% | Morgan Stanley | Matthew Harrison | $61 → $63 | Maintains | Overweight | Get Alert |
| 03/02/2023 | Buy Now | 228.64% | Oppenheimer | Jay Olson | $85 → $70 | Maintains | Outperform | Get Alert |
| 03/01/2023 | Buy Now | 186.38% | Morgan Stanley | Matthew Harrison | $65 → $61 | Maintains | Overweight | Get Alert |
| 02/28/2023 | Buy Now | 134.74% | Evercore ISI Group | Joshua Schimmer | $80 → $50 | Maintains | Outperform | Get Alert |
| 02/28/2023 | Buy Now | 392.96% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 78.4% | Wedbush | Laura Chico | $46 → $38 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 392.96% | HC Wainwright & Co. | Andrew Fein | → $105 | Reiterates | → Buy | Get Alert |
| 01/30/2023 | Buy Now | 134.74% | SVB Leerink | Marc Goodman | → $50 | Initiates | → Outperform | Get Alert |
| 01/25/2023 | Buy Now | 205.16% | Morgan Stanley | Matthew Harrison | $60 → $65 | Maintains | Overweight | Get Alert |
| 12/05/2022 | Buy Now | — | Cowen & Co. | Brendan Smith | — | Initiates | → Outperform | Get Alert |
| 11/08/2022 | Buy Now | 181.69% | Morgan Stanley | Matthew Harrison | $67 → $60 | Maintains | Overweight | Get Alert |
| 11/02/2022 | Buy Now | 87.79% | B of A Securities | Avikal Malik | → $40 | Initiates | → Buy | Get Alert |
| 06/23/2022 | Buy Now | 83.1% | Berenberg | Caroline Palomeque | → $39 | Initiates | → Buy | Get Alert |
| 05/24/2022 | Buy Now | 284.98% | Goldman Sachs | Salveen Richter | $99 → $82 | Maintains | Buy | Get Alert |
| 01/06/2022 | Buy Now | 327.23% | Morgan Stanley | Matthew Harrison | $99 → $91 | Maintains | Overweight | Get Alert |
| 09/21/2021 | Buy Now | 299.06% | Oppenheimer | Jay Olson | — | Initiates | → Outperform | Get Alert |
| 08/16/2021 | Buy Now | 364.79% | Morgan Stanley | Matthew Harrison | — | Maintains | Overweight | Get Alert |
| 07/26/2021 | Buy Now | 392.96% | HC Wainwright & Co. | Andrew Fein | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Denali Therapeutics (DNLI) stock?
The latest price target for Denali Therapeutics (NASDAQ:DNLI) was reported by HC Wainwright & Co. on May 8, 2024. The analyst firm set a price target for $95.00 expecting DNLI to rise to within 12 months (a possible 346.01% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Denali Therapeutics (DNLI)?
The latest analyst rating for Denali Therapeutics (NASDAQ:DNLI) was provided by HC Wainwright & Co., and Denali Therapeutics reiterated their buy rating.
When was the last upgrade for Denali Therapeutics (DNLI)?
There is no last upgrade for Denali Therapeutics
When was the last downgrade for Denali Therapeutics (DNLI)?
There is no last downgrade for Denali Therapeutics.
When is the next analyst rating going to be posted or updated for Denali Therapeutics (DNLI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Denali Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Denali Therapeutics was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
Is the Analyst Rating Denali Therapeutics (DNLI) correct?
While ratings are subjective and will change, the latest Denali Therapeutics (DNLI) rating was a reiterated with a price target of $95.00 to $95.00. The current price Denali Therapeutics (DNLI) is trading at is $21.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.